The podcast addressed topics such as the limitations of the ANA test, and what exam findings raise suspicion of autoimmunity.

Approximately 100 leading researchers and clinicians, research staff and trainees gathered to discuss innovative ways to advance research in arthritis, allergy and autoimmune diseases.

Dr. Nelson discussed the fact that exercise programs are often the ‘best medicine’ for managing pain and improving mobility, especially for people with osteoarthritis.

Her study was titled, “Sustained inhibition of CC-chemokine receptor-2 via intraarticular deposition of polymeric microplates in post-traumatic osteoarthritis.”

The Arthritis Foundation’s Osteoarthritis Clinical Trial Network (OACTN) is composed of clinical sites led by world-renowned OA investigators with focuses in musculoskeletal MRI, orthopedic surgery, rheumatology, and sports medicine.

Twenty four percent of patients who were reporting a penicillin allergy had their allergy label removed after a 5-minute pharmacy screening.

This novel, randomized clinical trial will evaluate if vitamin K supplementation impacts pain and function in patients with knee OA who are vitamin K insufficient.

The innovative research seeks to identify putative causal knee OA risk variants, map them to their target genes, and quantify their phenotypic impact in chondrocytes.

The research showed early deletion of Ccr2 in aggrecan-expressing cells reduces the initiation, but not the progression, of post traumatic osteoarthritis and its associated pain.

Read about TARC’s Strategic Planning Retreat, get an update from our Director, and learn about TARC grants, our upcoming Research Day and seminars, the key offerings of our CCCR, as well as spotlights/kudos for our team members.